Unity Biotechnology ( NASDAQ:UBX – Get Rating ) ‘s stock had its 'buy' rating restated by research analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $10.00 price target on the stock. HC Wainwright's price target points to a potential upside of 488.24% from the company's current price. Other analysts have also issued reports about the company. Mizuho dropped their price target on Unity Biotechnology from $12.00 to $6.00 and set a 'buy' rating on the stock in a report on Tuesday.

https://www.dailypolitical.com/2023/03/29/hc-wainwright-reiterates-buy-rating-for-unity-biotechnology-nasdaqubx.html

#dailypolitical